Management of septic shock in the pediatric emergency department in 2004

Clinical Pediatric Emergency Medicine

Volumn 5, Issue 1, 2004, Pages 20-27

  Saladino, Richard A ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; ANTIBIOTIC AGENT; CATECHOLAMINE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; DOPAMINE; DROTRECOGIN; GENTAMICIN; HYDROCORTISONE; INOTROPIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPID A; METRONIDAZOLE; MONOCLONAL ANTIBODY; PIPERACILLIN PLUS TAZOBACTAM; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL FEATURE; CRYSTALLOID; EMERGENCY WARD; FEVER; FLUID THERAPY; HEMODYNAMICS; HUMAN; HYPOTHERMIA; INFANT; INFECTION RISK; MYCOSIS; RESUSCITATION; RISK FACTOR; SEPTIC SHOCK; VASCULAR ACCESS; VIRUS INFECTION;

EID: 1842423788     PISSN: 15228401     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpem.2003.11.007     Document Type: Article

References (47)

1. Levy MM, Finck MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003.
2. Dellinger PR: Cardiovascular management of septic shock. Crit Care Med 31:946-955, 2003.
3. Carcillo JA, Fields MD: Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 30:1365-1378, 2002.
4. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time? Crit Care Med 26:2078-2086, 1998.
5. Angus DC, Linde-Zwirble WT, Liddicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care. Crit Care Med 29:1303-1310, 2001.
6. Stoll BJ, Holman RC, Shuchat A: Decline in sepsis-associated neonatal and infant deaths: 1979-1994, J Pediatr 102:e18, 1998.
7. Han YY, Carcillo JA, Dragotta MA, et al: Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 112:793-799, 2003.
8. Arnal LE, Stein F. Pediatric septic shocks: Why has mortality decreased? The utility of goal-directed therapy. Semin Pediatr Infect Dis 14:165-172, 2003.
9. Anonymous. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. MMWR Morb Mortal Wkly Rep 51:234-237, 2002.
10. Ceneviva G, Pachall JA, Maffei F, et al: Hemodynamic support in fluid refractory pediatric septic shock. J Pediatr 102:e19, 1998.
11. Pollock MM, Fields AI, Ruttiman UE, et al: Sequential cardiopulmonary variables of infants and children in septic shock. Crit Care Med 12:554-559, 1984.
12. Pollack MM, Fields AI, Ruttimann UE: Distributions of cardiopulmonary variables in pediatric survivors and non-survivors of septic shock. Crit Care Med 13:454-459, 1985.
13. Carcillo JA, Pollack MM, Ruttimann UE, et al: Sequential physiologic interactions in cardiogenic and septic shock. Crit Care Med 17:12-16, 1979.
14. Burns J, Arnold JH: Pediatric critical care. Curr Opin Pediatr 6:295-302, 1994.
15. Carcillo JA, Davis AI, Zaritsky A: Role of early fluid resuscitation in pediatric septic shock. JAMA 266:1242-1245, 1991.
16. Nhan NT, Phuong CXT, Kneen R, et al: Acute management of dengue shock syndrome: A randomized double-blind comparison of four intravenous fluid regimens in the first hour. Clin Infect Dis 32:204-212, 2001.
17. Pollard AJ, Britto J, Nadel S, et al: Emergency management of meningococcal disease. Arch Dis Child 80:290-296, 1999.
18. Cochrane Injuries Group Albumin Reviewers: Human albumin administrations in critically ill patients: Systematic review of randomized controlled trials. BMJ 317:235-240, 1998.
19. American College of Chest Physicians/Society of Critical Care Medicine consensus conference: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
20. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis in septic shock. N Engl J Med 346:1368-1377, 2001.
21. Padbury JF, Agata Y, Baylen BG, et al: Pharmacokinetics of dopamine in critically ill newborn infants. J Pediatr 117:472-476, 1990.
22. Bhatt-Mehta V, Nahara MC, McClead RE, et al: Dopamine pharmacokinetics in critically ill newborn infants. Eur J Clin Pharmacol 25:181-189, 1991.
23. Saladino R, Bachman D, Fleisher G: Arterial access in the pediatric emergency department. Ann Emerg Med 19:382-385, 1990.
24. Sumarmo: The role of steroids in dengue shock syndrome. Southeast Asian J Trop Med Public Health 18:383-389, 1987.
25. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low dose of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871, 2002.
26. Remick DG: Cytokine therapeutics for the treatment of sepsis: Why has nothing worked? Curr Pharmacol Design 9:75-82, 2003.
27. Dinarello CA: Anti-cytokine therapies in response to systemic infection. J Invest Dermatol Sympos Proceed 6:244-250, 2001.
28. Finch RG: Design of clinical trials in sepsis: Problems and pitfalls. J Antimicrob Chemother 41:A95-102, 1998.
29. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25:1095-1100, 1997.
30. Ely EW, Angus DC, Williams MD, et al: Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 37:187-195, 2003.
31. McCoy C, Matthews SJ: Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. Clin Therapeut 25:396-421, 2003.
32. Vincent JL, Angus DC, Artigas A, et al: Recombinant Human Activated Protein C Worlwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotregocin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834-840, 2003.
33. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
34. de Kleijn ED, de Groot R, Hack CE, et al: Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31:1839-1847, 2003.
35. Barton P, Kalil AC, Nadel S, et al: Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 113:7-17, 2004.
36. Angus DC, Birmingham MC, Balk RA, et al: E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial. JAMA 283:1723-1730, 2000.
37. Saladino RA, Fleisher GR, Siber GR, et al: Therapeutic potential of a recombinant endotoxin-neutralizing protein from Limulus polyphemus, in: Morrison DC, Ryan JL (eds): Novel Therapeutic Strategies in the Treatment of Sepsis. New York, NY, Marcel Dekker, Inc, 1995, pp. 97-110.
38. Hellman J, Warren HS: Antiendotoxin strategies. Infect Dis Clin North Am 13:371-386, 1999.
39. Giroir BP, Quint PA, Barton P, et al: Preliminary evaluation of recombinant amino terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal disease. Lancet 350:1439-1443, 1997.
40. Ulevitch RJ: New therapeutic targets revealed through investigations of innate immunity. Crit Care Med 2001 29:S8-S12, 2001.
41. Fisher CJ, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12-21, 1994.
42. Fisher CJ, Dhainaut JF, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double blind, placebo-controlled trial. JAMA 271:1836-1843, 1993.
43. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351:929-933, 1998.
44. Gallagher J, Fisher C, Sherman B, et al: A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Inten Care Med 27:1169-1178, 2001.
45. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 29:765-769, 2001.
46. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 29:S121-S125, 2001.
47. Rabinovici R: Platelet activating factor inhibition in sepsis: The end? Crit Care Med 31:1861-1862, 2003.